Ignyta Inc. (NASDAQ:RXDX)’s share price rose 2.1% on Friday . The stock traded as high as $5.78 and last traded at $5.72, with a volume of 112,857 shares changing hands. The stock had previously closed at $5.60.

RXDX has been the subject of several research reports. Jefferies Group reaffirmed a “buy” rating and issued a $20.00 target price on shares of Ignyta in a research report on Monday, April 18th. Cantor Fitzgerald reissued a “buy” rating on shares of Ignyta in a research report on Wednesday, June 8th. JPMorgan Chase & Co. initiated coverage on Ignyta in a research report on Thursday, June 23rd. They set an “overweight” rating and a $15.00 price objective for the company. Piper Jaffray Cos. reissued an “overweight” rating and set a $32.00 price objective on shares of Ignyta in a research report on Monday, April 18th. Finally, Leerink Swann reissued a “buy” rating on shares of Ignyta in a research report on Thursday, May 12th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $18.07.

The firm’s market capitalization is $238.21 million. The firm has a 50 day moving average of $5.81 and a 200-day moving average of $7.44.

Ignyta (NASDAQ:RXDX) last posted its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by $0.11. On average, equities analysts forecast that Ignyta Inc. will post ($2.72) EPS for the current year.

In other Ignyta news, Director Alexander W. Casdin acquired 232,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 4th. The stock was bought at an average price of $6.25 per share, with a total value of $1,450,000.00. Following the completion of the purchase, the director now owns 100,000 shares of the company’s stock, valued at $625,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Ignyta, Inc is an oncology biotechnology company. The Company focuses on an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Its Rx is focused on discovering, in licensing or acquiring, then developing and commercializing molecularly targeted therapies that, sequentially or in combination, are foundational for eradicating residual disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.